Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Am J Hematol. 2020 Dec 24;96(3):282–291. doi: 10.1002/ajh.26061

Fig 1.

Fig 1.

a. Overall survival (OS) in patients who received 10-day decitabine with venetoclax (DEC10-VEN) and intensive chemotherapy (IC), b. OS in patients with high treatment-related mortality risk score (TRMS >13.1), c. OS in patients with low risk of TRM (TRMS ≤13.1), d. OS with DEC10-VEN in patients at high and low risk of TRM, e. forest plot of exploratory subgroup analyses. FLT3 inhibitors were administered in 10 out of 14 FLT3mut patients in the DEC10-VEN cohort and 15 out of 73 patients in IC cohort. ECOG PS = Eastern Co-operative Oncology Group Performance Status, BM = bone marrow, AHD = antecedent hematological disorder.